# EDGAR Filing Document

**Accession Number:** 0001611747
**File Stem:** 0001213900-26-066166
**Filing Date:** 2026-6
**Character Count:** 4499
**Document Hash:** 2e245cdc149a2502ab1eebbba64bfcf0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-066166.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001213900-26-066166

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260608

**FILED AS OF DATE**: 20260608

**DATE AS OF CHANGE**: 20260608

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scinai Immunotherapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001611747
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37353
- **FILM NUMBER:** 261071885

**BUSINESS ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000
- **BUSINESS PHONE:** 972-8-9302529

**MAIL ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BiondVax Pharmaceuticals Ltd.
- **DATE OF NAME CHANGE:** 20140624

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2026

Commission File Number: 001-37353

**SCINAI IMMUNOTHERAPEUTICS LTD.**

(Translation of registrant's name into English)

**Jerusalem BioPark, 2nd Floor**

**Hadassah Ein Kerem Campus**

**Jerusalem, Israel**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**NOTICE TO SHAREHOLDERS REGARDING PROXY STATEMENT** 

**FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS** 

**SCHEDULED FOR JUNE 16, 2026**

On May 12, 2026, Scinai Immunotherapeutics Ltd. (the "<u>Company</u>") furnished to the Securities and Exchange Commission a Form 6-K containing a Notice and Proxy Statement in connection with the Company's Annual General Meeting of Shareholders (the "<u>Meeting</u>"), scheduled for June 16, 2026 (the "<u>Proxy Statement</u>"). Proposal No. 6 in the Proxy Statement relates to the extension of the term of the Services Agreement with Mr. Mark Germain, the Company's Chairman of the Board.

The Proxy Statement provides that the Services Agreement would expire upon the expiration of the current term of service of Mr. Germain as a director. The Proxy Statement inadvertently refers to the expiration of Mr. Germain's current term of service as a director as being the second anniversary of the Meeting. For the sake of clarity, Mr. Germain's term of service as a director, as previously approved by the Company's shareholders, is until the second annual meeting of shareholders after the Meeting, and, if Proposal No. 6 is approved, the extended Services Agreement would expire at that time.

This Report on Form 6-K is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File Nos. [333-291460](http://www.sec.gov/Archives/edgar/data/1611747/000121390025109050/ea0264993-s8_scinai.htm), [333-271293](http://www.sec.gov/Archives/edgar/data/1611747/000121390023030288/ea176534-s8_biondvaxpharma.htm) and [333-239344](http://www.sec.gov/Archives/edgar/data/1611747/000121390020015429/ea123060-s8_biondvaxpharma.htm)) and Form F-3 (File Nos. [333-295698](http://www.sec.gov/Archives/edgar/data/1611747/000121390026053855/ea0289625-f3_scinai.htm), [333-274078](http://www.sec.gov/Archives/edgar/data/1611747/000121390023068963/ea183844-f3_biondvaxpharma.htm) and [333-276767](http://www.sec.gov/Archives/edgar/data/1611747/000121390024007939/ea192382-f3_scinaiimmun.htm)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Scinai Immunotherapeutics Ltd.** | **Scinai Immunotherapeutics Ltd.** |
| Date: June 8, 2026 | By: | /s/ Amir Reichman |
|  |  | Amir Reichman |
|  |  | Chief Executive Officer |

---